Medchemexpress LLC Crizotinib-d5 | 1395950-84-1 | 99.6% | C₂₁H₁₇D₅Cl₂FN₅O | 1 MG

Supplier:  Medchemexpress LLC HY50878S1MG

Crizotinib-d5 is the deuterium labeled version of Crizotinib. Crizotinib functions as an orally bioavailable, ATP-competitive inhibitor targeting ALK and c-Met, with IC50s of 20 nM and 8 nM, respectively. It effectively inhibits tyrosine phosphorylation of NPM-ALK and c-Met in cell-based assays, exhibiting IC50s of 24 nM and 11 nM. Crizotinib also acts as a ROS1 inhibitor and demonstrates effective tumor growth inhibition.

• Deuterium labeled crizotinib.
• Orally bioavailable.
• Functions as an ATP-competitive ALK and c-Met inhibitor.
• Inhibits tyrosine phosphorylation of NPM-ALK and c-Met in cell-based assays.
• Acts as a ROS1 inhibitor.
• Demonstrates effective tumor growth inhibition.
• Suitable for use as a tracer.
• Can serve as an internal standard for quantitative analysis using methods like NMR, GC-MS, or LC-MS.

Catalog No. 50-003-57753